Martine Poelman
Overview
Explore the profile of Martine Poelman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
158
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Besliu C, Tanase A, Rotaru I, Espinoza J, Vidal L, Poelman M, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941892
Multiple myeloma is biologically and clinically a complex and heterogeneous disease which develops late in life, with the median age at the time of initial diagnosis being 66 years. In...
2.
Czajka-Francuz P, Prendes M, Mankan A, Quintana A, Pabla S, Ramkissoon S, et al.
Front Oncol
. 2023 Jul;
13:1200646.
PMID: 37427115
The efficacy of cancer therapies is limited to a great extent by immunosuppressive mechanisms within the tumor microenvironment (TME). Numerous immune escape mechanisms have been identified. These include not only...
3.
Saini K, de Las Heras B, de Castro J, Venkitaraman R, Poelman M, Srinivasan G, et al.
Lancet Haematol
. 2020 Apr;
7(6):e432-e435.
PMID: 32339482
No abstract available.
4.
Postel-Vinay S, Herbschleb K, Massard C, Woodcock V, Soria J, Walter A, et al.
Eur J Cancer
. 2019 Feb;
109:103-110.
PMID: 30711772
Background: Bromodomain and extraterminal motif (BET) protein inhibition is a promising cancer treatment strategy, notably for targeting MYC- or BRD4-driven diseases. A first-in-human study investigated the safety, pharmacokinetics, maximum tolerated...
5.
Hansson M, Gimsing P, Badros A, Martinsson Niskanen T, Nahi H, Offner F, et al.
Clin Cancer Res
. 2015 Feb;
21(12):2730-6.
PMID: 25712687
Purpose: This multicenter, first-in-human study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of BI-505, a human anti-ICAM-1 monoclonal antibody, in advanced relapsed/refractory multiple myeloma patients. Experimental Design: BI-505 was given intravenously,...